2FIRSTS Analysis of China's E-cigarette Exports to Japan in February, 2024

Industry Insight by 2FIRSTS
Apr.08.2024
2FIRSTS Analysis of China's E-cigarette Exports to Japan in February, 2024
China's e-cigarette exports to Japan in February 2024 saw a significant decline in both value and quantity.

According to the latest trade data released by the General Administration of Customs of the People's Republic of China, 2FIRSTS has compiled the e-cigarette export data to Japan for February 2024 as follows:

 

2月中国出口日本电子烟约2321.8万美元 环比下降15.65%
Image source: 2FIRSTS (created by Mincy)

 

The export volume was approximately $23.218 million, a decrease of 15.65% compared to the previous period and a decrease of 37.08% year-on-year.

 

2月中国出口日本电子烟约2321.8万美元 环比下降15.65%
Image source: 2FIRSTS (created by Mincy)

 

The export volume is approximately 131 tons, showing a month-on-month decrease of 20.87% and a year-on-year decrease of 47.21%.

 

2月中国出口日本电子烟约2321.8万美元 环比下降15.65%
Image source: 2FIRSTS (Chart by Mincy)

 

The export unit price is $176.55 per kilogram, which is an increase of 6.60% compared to the previous period and an increase of 19.19% year-on-year. The average price of "e-cigarettes and similar personal electronic vapor devices" is $39.36 per unit.

 

2月中国出口日本电子烟约2321.8万美元 环比下降15.65%
Image source: 2FIRSTS (created by Mincy)

 

e-cigarettes and similar personal electronic vapor devices" account for 100% of the export category, while "non-combustible products containing nicotine without tobacco or reconstituted tobacco" account for 0% of the total.

 

2FIRSTS Analysis of China's E-cigarette Exports to Japan in February, 2024
Image source: 2FIRSTS (Created by Mincy)

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
Law360 reports that a Fifth Circuit panel expressed skepticism about the FDA’s claim that it has no de facto ban on flavored refillable e-cigarette products, noting that only six applications had been approved out of hundreds of thousands and that near-100% denials look like a ban.
Jan.07 by 2FIRSTS.ai
U.S. vape firms appeal Mississippi synthetic-nicotine ban, citing FDA authority preemption
U.S. vape firms appeal Mississippi synthetic-nicotine ban, citing FDA authority preemption
A coalition of U.S. vape industry groups has appealed a Mississippi law banning the sale of e-cigarette products containing synthetic nicotine, arguing the statute effectively conditions sales on FDA authorization and unlawfully encroaches on federal regulatory authority. The law took effect in July 2025 and has already begun to be enforced.
Dec.17 by 2FIRSTS.ai
Heno Biotech Invited to Speak at PouchEX 2025 in Stockholm, Introduces Supply Chain Competency Model for the Nicotine Pouch Industry
Heno Biotech Invited to Speak at PouchEX 2025 in Stockholm, Introduces Supply Chain Competency Model for the Nicotine Pouch Industry
Heno Biotech was invited to deliver a keynote address at PouchEX Stockholm 2025, presenting a new supply chain competency model for the nicotine pouch sector. The company showcased its end-to-end capabilities—from scientific research and advanced manufacturing to global regulatory compliance—underscoring the critical role of supply chain upgrading in driving sustainable industry growth.
Nov.24
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
Single-Use Vape Ban Bill Sparks Debate in Irish Parliament
Single-Use Vape Ban Bill Sparks Debate in Irish Parliament
A bill seeking to ban the sale of single-use vapes has been introduced to Ireland’s Dáil, with lawmakers citing environmental damage and rising concerns over youth health. Industry representatives have urged full scrutiny of the bill, warning of enforcement challenges and potential loopholes.
Dec.18 by 2FIRSTS.ai